Objective: The study aim was to investigate the long-term prognosis and risk factors of postpericardiotomy syndrome (PPS).
See Editorial Commentary page 886.
Postpericardiotomy Syndrome (PPS) is a common complication of cardiac surgery. 1 The syndrome is associated with early postoperative problems such as prolonged hospital stay and cardiac tamponade. 2, 3 The long-term prognosis of PPS has not been studied extensively. PPS is thought to be related to inflammation and autoimmune phenomena in response to surgical trauma and use of cardiopulmonary bypass. 1, 4 In a subanalysis of the Dexamethasone for Cardiac Surgery (DECS) trial, 5 we found no protective effect of 1.0 mg/kg dexamethasone on the incidence of PPS. 6 In the present study, we investigated the short-term (1 month) and long-term (1 year) prognosis of PPS. Furthermore, we searched for risk factors of PPS, to better identify patients who are at risk of PPS and to be more alert on adverse events in these patients.
MATERIALS AND METHODS Study Design and Population
The study population consisted of 822 patients enrolled in the DECS trial. The DECS trial was a double blind, randomized, placebo-controlled trial investigating the effect of an intraoperative dose of 1 mg/kg dexamethasone on a composite end point of death, myocardial infarction, stroke, renal failure, or respiratory failure, in 4494 adult patients undergoing cardiac surgery. 5 The population of the present study consists of a subgroup of 822 patients undergoing valve surgery at a single center (University Medical Center Utrecht, Utrecht, the Netherlands) and who were included in the earlier published DECS PPS substudy. 6 In the DECS PPS substudy, 852 DECS patients initially underwent valve surgery. Thirty patients (3.5%) were excluded because no postoperative echocardiography was available (n ¼ 20) or other follow-up data needed to establish the diagnosis of PPS were missing (n ¼ 10). The remaining 822 patients were included for data analyses. The study consisted of patients undergoing valve surgery only because of the availability of routine surveillance echocardiography, usually on postoperative days 4 to 6.
PPS was diagnosed if 2 out of 5 of the following symptoms were present: pericardial rubbing, fever > 72 hours postoperative, pleuritic chest pain, new significant pleural effusion on chest radiograph (above the highest level of the diaphragm), or significant pericardial effusion (! 10 mm). In the main study, all patients provided written informed consent before randomization. The Research Ethics Committee at each participating center approved the protocol, which contained the protocol of the present substudy.
Clinical Outcomes
The primary outcome was the incidence of reoperation for tamponade in patients with and without PPS at 1 year. Reoperation for tamponade was defined as a resternotomy or subxiphoid incision because of excessive pericardial fluid causing echocardiographic or clinical features of cardiac tamponade.
Long-term secondary outcomes at 1 year were mortality, stroke, myocardial infarction, and readmissions (for any reason). Myocardial infarction was defined according to the criteria of the universal definition of myocardial infarction. 7 Stroke was defined as a neurologic deficit lasting >24 hours, with increased invalidity (Rankin scale increase, ! 1 point) and signs of a new ischemic cerebral infarction on computed tomography or magnetic resonance imaging scan.
Short-term secondary outcomes were total hospital stay in days and at 1 month the incidences of postoperative atrial fibrillation, reoperation for tamponade, reoperation for surgical bleeding, and percutaneous pericardial or pleural puncture. Postoperative atrial fibrillation (AF) was defined by the occurrence of any episode of AF postoperatively (during ! 10 seconds on a 12-channel electrocardiogram or 3-channel rhythm recording), regardless of a medical history of AF.
Data Collection
Mortality, stroke, and myocardial infarction within 1 year after cardiac surgery and total hospital stay in days were collected prospectively as part of the original DECS trial.
Data concerning postoperative AF, reoperations, and pleural and pericardial puncture were collected by examining all surgical reports, medical records, discharge letters, and postoperative electrocardiograms. Detailed information regarding data collection on postoperative AF and reinterventions can be found in the earlier published DECS postoperative AF study 8 and the DECS rethoracotomy study. All participants were followed for 1 year after their initial surgery. In case of a hospital readmission, medical reports were collected retrospectively and assessed by an investigator, who was blinded regarding diagnosis of PPS.
Postoperative Anticoagulant Therapy and Chest Tube Management
The standard postoperative anticoagulation regimen was as follows: The first moment that drain output was <50 mL in the past hour and <100 mL in the past 3 hours, all patients received low molecular weight heparin (LMWH) 2500 IU subcutaneously. If the patient also underwent a coronary artery bypass grafting (CABG), a single intravenous dose of 450 mg acetylsalicylic acid was added.
On the first postoperative morning, all patients received 2500 IU LMWH subcutaneously and in case of a CABG (or preoperative acetylsalicylic acid use), a daily oral dose of 100 mg acetylsalicylic acid was (re)started.
From the evening of the first postoperative day, daily thrombosis prophylaxis was started: LMWH 2500 IU subcutaneously for patients weighing <80 kg and 5000 IU subcutaneously for patients weighing > 80 kg. Also coumarin therapy was initiated, with target international normalized ratios of 2.5 to 3.5. If the international normalized ratio was > 2.0, LMWH therapy was stopped. Coumarin therapy was continued for 3 months in patients receiving a bioprosthetic valve or valve repair and lifelong for patients receiving a mechanical valve prosthesis.
Chest tubes were removed if the production was decreasing to<60 mL over the past 3 hours, usually on the first postoperative day. , and all other baseline variables with a P value <.10 in univariable analysis were entered in multivariable analysis using logistic regression.
Statistical Analysis
We also used multivariable logistic and linear regression analysis to adjust the association between PPS and primary and secondary outcomes for the following confounders: European System for Cardiac Operative Risk Evaluation score (as an overall measure of operative risk), treatment with intraoperative use of study medication (ie, dexamethasone), and other baseline characteristic differences with a P value <.10. Freedom of reoperation for tamponade was compared using Kaplan-Meier survival analysis with log rank analysis. The incidences of 1-year outcomes are the Kaplan-Meier estimate of the rate of the end point. IBM SPSS version 21 (IBM-SPSS Inc, Armonk, NY) was used for all analyses.
RESULTS
PPS occurred in 119 of 822 patients (14.5%). PPS was usually diagnosed on postoperative day 4 to 6, because at that time, a routine postoperative chest radiograph and echocardiography (needed to establish the diagnosis of PPS) were performed. However, if there was a clinical indication to perform additional investigations at a later moment in the postoperative course, PPS could also be diagnosed afterward. Baseline characteristics of the patients with and without PPS are listed in Table 1 . BMI, the rate of preoperative corticosteroid use, and the rate of prior stroke were significantly lower in patients with PPS. The incidence of treatment for pulmonary disease without corticosteroids and mitral valve surgery were higher in patients with PPS.
Risk Factors of PPS
In univariable analyses of baseline characteristics (Table 1) , a higher BMI (OR per point increase, 0.93; 95% CI, 0.88-0.98; P ¼ .001), prior stroke (OR, 0.31; 95% CI, 0.11-0.85; P ¼ .015), and preoperative corticosteroid use (OR, 0.24; 95% CI, 0.08-0.79; P ¼ .007) were associated with a lower risk of PPS, whereas mitral valve surgery (OR, 1.64; 95% CI, 1.11-2.43; P ¼ .018) and treatment for pulmonary disease without corticosteroids (OR, 2.42; 95% CI, 1.27-4.63; P ¼ .011) were associated with a higher risk of PPS. After multivariable logistic regression analysis (Table 2) , a higher BMI (OR per point increase, 0.94; 95% CI, 0.89-0.99; P ¼ .028) remained as an independent protective factor of PPS. Treatment for pulmonary disease without corticosteroids (OR, 2.55; 95% CI, 1.25-5.20; P ¼ .010) was independently associated with a higher risk of PPS.
Effects of PPS on Clinical Outcomes
The clinical outcomes are listed in Table 3 . Follow-up data were complete in all 822 patients, except for duration of hospital stay (12 cases missing [1.5%]).
The estimated incidence of a reoperation for tamponade within 1 year after cardiac surgery was 20.9% in patients with PPS versus 2.5% in no-PPS patients (OR, 10.19; 95% CI, 5.28-19.67; P <.001). A survival curve of reoperation for tamponade is depicted in Figure 1 . All reoperations for tamponade occurred in the first 65 days after surgery and in all cases, PPS was diagnosed before the rethoracotomy for tamponade took place. Of the 41 patients who underwent a reoperation for tamponade, 11 patients underwent a subxiphoid drainage (Video 1), 6 patients initially underwent a pericardial puncture and afterward a resternotomy (5 patients) or subxiphoid drainage (1 patient), and 24 patients underwent a resternotomy as initial choice. The pericardial puncture in the 6 patients who required an additional surgical procedure afterward was unsuccessful in 1 patient, complicated by right ventricular puncture in 2 patients, and 3 patients had recurrence of pericardial fluid after the puncture.
Median duration of hospital stay was 13 (IQR, 9-18) days in the PPS group and 11 (IQR, (8) (9) (10) (11) (12) (13) (14) (15) days in the no-PPS group (P ¼ .001). Patients with PPS underwent significantly more reinterventions within 30 days after cardiac surgery compared with the no-PPS group; reoperation for tamponade occurred in 17.6% versus 2.4% of the patients, respectively (OR, 8.65; 95% CI, 4.41-16.96; P <.001) and pericardial puncture in 7.6% versus 0.6%, respectively, (OR, 14.30; 95% CI, 4.33-47.23; P <.001). There were no significant differences in the incidence of reoperation for surgical bleeding, pleural puncture, postoperative AF, mortality, stroke, myocardial infarction, and readmissions between the 2 groups. Of the 15 patients who underwent an early reoperation for surgical bleeding, 4 patients developed PPS afterward.
Regression Analyses
We adjusted the association between the presence of PPS and the primary and secondary outcomes for the following variables using multivariable regression analysis: age, BMI, history of stroke, treatment for pulmonary disease without corticosteroids, preoperative corticosteroid use, dexamethasone treatment, European System for Cardiac Operative Risk Evaluation score, aortic valve surgery, and mitral valve surgery. Adjusted ORs and P values are listed in Table 4 . After adjustment, the risk of reoperation for tamponade (at 1 month and 1 year after cardiac surgery), pericardial puncture at 1 month, and the total length of hospital stay remained significantly higher in the PPS group.
DISCUSSION
The present study is among the largest cohort studies of PPS investigating both risk factors and long-term prognosis of PPS in valve surgery patients. In our study, PPS was associated with an increased incidence of reinterventions for tamponade. PPS was also associated with significantly longer postoperative hospitalization. There was no difference in the number of reoperations for tamponade in the first 5 postoperative days. Most likely, reoperations for tamponade that occur in the first 5 postoperative days represent common bleeding-related complications after cardiac surgery. After 5 days, the incidence of reoperations for tamponade in PPS patients increased significantly compared with patients without PPS, suggesting a different underlying mechanism of early versus late tamponade. The higher incidence of reinterventions in patients with PPS did not lead to differences in long-term outcome. Survival and readmissions at 1 year after cardiac surgery did not differ between the 2 study groups. The findings of the present study partially correspond with results of prior reports on the prognosis of PPS. Differences in study design, study population, and definition of PPS may explain these discrepancies.
The most recent study, performed by Lehto and colleagues, 10 investigated the prognosis of PPS in 688 patients undergoing CABG. There were no differences in total hospital stay and the incidence of resternotomy between patients with and without PPS. 10 Chest radiograph and echocardiography results were not available for all of the 688 patients. Furthermore, no thresholds for minimal amounts of pleural and pericardial effusion were used. This and the difference in study population (CABG vs valve surgery) may be a reason for the different findings. A study by Imazio and colleagues 3 in 360 patients undergoing any type of cardiac surgery found longer hospital stays in patients with PPS, which is confirmed by our study. In contrast to our study, that study also reported significantly more readmissions in the PPS group. 3 The incidence of tamponade was remarkably lower than in our study: 1.9% in patients with PPS. 3 Another study by Alraies and colleagues, 2 which investigated 239 patients with PPS, found a higher incidence of reinterventions, namely 31%. In our study, the rate of reoperation for tamponade was 20.9% in the PPS group. In the main study of 4494 patients, dexamethasone treatment was associated with an increased rethoracotomy risk. 9 However, in the present study there was no difference in baseline dexamethasone use in patients with and without PPS. Furthermore, we investigated dexamethasone treatment in the multivariable analysis; therefore, it is unlikely that this is the reason for the high incidence of reoperations in PPS patients. To perform a full resternotomy or a less-invasive approach was at the discretion of the attending surgeon and was based on factors such as expected active bleeding, the location of the pericardial effusion, and presence of intrapericardial thrombus. Pericardial puncture has the advantage of being less invasive and can be performed with local anesthetic only. However, in some cases this approach might be unsuccessful and an additional surgical intervention might be required. Furthermore, pericardial puncture has been associated with higher recurrence rates due to incomplete fluid evacuation and carries the risk of a complicated ventricular puncture. 11, 12 These findings were confirmed in our study. Given the high incidence of reoperations for tamponade, we believe that PPS is an important complication of cardiac surgery leading to prolonged hospital stay. Preventing PPS might thus be worthwhile, in particular for patient comfort and cost-effectiveness. For this reason, we aimed to identify preoperative risk factors of PPS.
Remarkably, a higher BMI was independently associated with a lower risk of PPS. The finding that a higher BMI was negatively associated with PPS has been reported before 13 ; however, in more recent studies a lower BMI was not associated with PPS.
10,14 A possible explanation for higher BMI as protective factor of PPS can be the immunomodulatory effects of obesity. Excessive visceral fat is associated with increased interleukin (IL) 6 production and chronic, subclinical, systemic inflammation. 15, 16 On the other hand, a higher BMI is also associated with higher levels of antiinflammatory ILs, 17 which might protect against PPS. Although we did not demonstrate a protective effect of a single intraoperative dose of 1 mg/kg dexamethasone on the occurrence of PPS, 6 chronic corticosteroid use was associated with a reduced incidence of PPS in univariable analysis. This finding supports the hypothesis of a postoperative ongoing inflammatory process. Corticosteroids inhibit the synthesis of IL-8 and other proinflammatory mediators, and may therefore protect against PPS. 14 However, after multivariable analysis there was no significant association between chronic corticosteroid use and PPS anymore, questioning the potential efficacy of corticosteroid treatment for the prevention of PPS. Earlier trials investigating corticosteroid treatment for the prevention of PPS also do not show convincing evidence in favor of corticosteroids. 6, 18, 19 In our study, treatment for pulmonary disease was defined as pulmonary disease requiring daily inhaled maintenance treatment with bronchodilators and/or corticosteroids. Because there was a strong relation between treatment for pulmonary disease and corticosteroid use, we only included treatment for pulmonary disease without corticosteroids in the multivariable model. After multivariable logistic regression analysis, treatment for pulmonary disease without corticosteroids was associated with a higher risk of PPS. A possible explanation could be that patients with chronic pulmonary inflammation are more vulnerable to develop systemic and pericardial inflammation; however, this finding has never been reported before.
An earlier study showed that transfusion of 1 or more units of red blood cells was associated with a higher risk of PPS, 10 suggesting that bleeding may play a role in the development of PPS. Retained blood in the pericardial and pleural space is believed to induce a local inflammatory response that can lead to effusions. [20] [21] [22] However, in our study transfusion of packed red cells was not associated with an increased risk of PPS. It has been suggested that increasing age is associated with a lower risk of PPS due to a senescent immune system in elderly persons. 13, [23] [24] [25] In other studies and in our study, this protective effect of aging could not be confirmed. 3, 10 Use of CPB has also been suggested as a possible etiologic factor of PPS and might lead to more reoperations, 26 although duration of CPB was not associated with PPS in our study.
A strength of our study is the relatively large size of the study population and the fact that investigators were blinded to the diagnosis of PPS during data collection. A limitation of this study is that some data were collected retrospectively. Therefore, it was not possible to collect all clinically important variables, such as colchicine use, pericardial closure, and use of a pleural window. Also, no long-term data were available to evaluate the development of constrictive pericarditis; however, no patient underwent a reoperation because of constrictive pericarditis during the first year after surgery. We thoroughly collected all other available data and used the prospectively available dataset of the DECS trial. We therefore believe that there is a low risk of having missed important clinical outcomes. Another limitation is the study population that consisted of valve surgery patients only, because of the availability of routine postoperative echocardiography in these patients. Furthermore, because of the current definition of PPS, it is likely that some patients may fall within the definition of PPS without having clinically relevant PPS. By only scoring pericardial effusions ! 10 mm and pleural effusions above the level of the diaphragm, we aimed to minimize this probability.
CONCLUSIONS
Despite longer hospital stays and more short-term reoperations for tamponade, patients with PPS had an excellent 1-year prognosis.
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